Family history of pre-eclampsia as a predictor for pre-eclampsia in primigravidas

Family history of pre-eclampsia as a predictor for pre-eclampsia in primigravidas
复制标题

DOI:
10.1016/s0020-7292(97)00241-5
复制
发表时间:
1998-01-01
影响因子:
3.8
通讯作者:
Brennecke, SP
Brennecke, SP
中科院分区:
医学4区
文献类型:
--
作者:
Cincotta, RB;Brennecke, SP

文献摘要

被引文献

相似文献

目的:评估先兆子痫家族史知识作为先兆子痫发生的预测因子的临床效用。方法:前瞻性研究368例产科教学医院门诊的初产妇。从妇女那里获得任何先兆子痫家族史的详细信息,并观察其随后的产科结局。结果:368例初产妇中,34例(9.2%)发生子痫前期。总组中有18名(4.9%)妇女表示,她们的母亲(12名)、姐妹(5名)或两者(1名)患有先兆子痫。在这18名妇女中,5名(27.8%)发展为先兆子痫。在无家族史的妇女中,29例(8.3%)发生先兆子痫(相对危险度,RR = 3.4; 95%CI,1.5-7.6; P = 0.018)。有阳性家族史的妇女中有4名(22.2%)发展为重度先兆子痫,而有阴性家族史的妇女中有18名(5.1%)发展为重度先兆子痫(RR = 4.3; 95%CI,1.6-11.5; P = 0.017)。结论:在妊娠晚期,先兆子痫家族史与重度先兆子痫风险增加4倍相关。这一临床病史确定了一组在妊娠期间需要密切临床监测的人群,他们可能适合进行预防性干预试验。(C)1998年国际妇产科联合会。
Objective: To assess the clinical utility of knowledge of a family history of pre-eclampsia as a predictor for the development of pre-eclampsia in primigravid women. Methods: 368 primigravid women were prospectively recruited from the outpatients department of an obstetric teaching hospital. Details of any family history of pre-eclampsia were obtained from the women and their subsequent obstetric outcomes were observed. Results: Of 368 primigravid women, 34 (9.2%) developed pre-eclampsia. Eighteen (4.9%) women of the total group stated that they had a mother (12), sister (five) or both (one) who had had pre-eclampsia. Of these 18 women, five (27.8%) developed pre-eclampsia. Of the women who had no family history, 29 (8.3%) developed pre-eclampsia (relative risk, RR = 3.4; 95% CI, 1.5-7.6; P = 0.018). Four (22.2%) of the women with a positive family history developed severe pre-eclampsia compared to 18 (5.1%) with a negative family history (RR = 4.3; 95% CI, 1.6-11.5; P = 0.017). Conclusions: In a primigravida, a family history of pre-eclampsia is associated with a fourfold increased risk of severe pre-eclampsia. This clinical history identifies a group who warrant close clinical surveillance during pregnancy and who may be suitable for trials of prophylactic interventions. (C) 1998 International Federation of Gynecology and Obstetrics.